explore -WSS

explore

author：Wikipedia 2025-10-01 14:15:41 - browse：6612

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Canadians with cystic fibrosis outlive Americans by a decade

hotspot

WSS

The wait for US passports is creating travel purgatory and snarling summer plans

Security flaws in third

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Hubble vs. James Webb telescope images: See the difference

CDC advisory panel says seniors 'may' get RSV vaccine

The wait for US passports is creating travel purgatory and snarling summer plans

focus

explore

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca challenges Medicare drug negotiation program

At least 13 dead in Texas as scorching temps continue

STAT wants to know your pick for a great summer read or listen

As demand for Covid shots wanes, Moderna seeks its next success

How to make Best Hospitals ratings actually useful for patients

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A letter from the executive editor: The 2023 STATUS List

At least 13 dead in Texas as scorching temps continue

Dexcom's push to bring CGM to type 2 diabetes patients

hotspot

Neuroscience startup Neumora files for IPO

Use doctors trained outside the U.S. to ease the physician shortage

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

CDC advisory panel says seniors 'may' get RSV vaccine

Diversity in medical illustrations gets boost from Chidiebere Ibe

hotspot

entertainment

focus

hotspot